This page contains affiliate links. We may earn a commission at no extra cost to you.

$40–$80 for a 60-day supply

Check Price on Amazon
Evidence: Moderate-Strong — multiple RCTs and a 2017 meta-analysis of 12 RCTs (n=1,188) found PEA produced statistically significant, clinically meaningful pain reduction in neuropathic pain conditions. Available in Europe as a regulated medical food (Normast) for neuropathic pain.

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide produced naturally by cells throughout the body — including peripheral nerve cells and immune cells — as part of the body’s self-regulatory response to inflammation and pain. Discovered in the 1950s and researched extensively by Nobel Prize laureate Rita Levi-Montalcini, PEA modulates pain and inflammation through mechanisms that include activation of peroxisome proliferator-activated receptor-alpha (PPAR-α), modulation of mast cells, and indirect modulation of the endocannabinoid system — without binding cannabinoid receptors directly and without psychoactivity. Multiple meta-analyses and systematic reviews have concluded that PEA significantly reduces neuropathic pain across several conditions, including diabetic neuropathy, sciatica, CIPN, and postherpetic neuralgia. It is available in Europe as a medical food (Normast) and as a dietary supplement in the US. It is one of the most evidence-supported supplements for neuropathic pain that many physicians are not yet familiar with.

How It Works

PEA exerts its effects primarily through PPAR-α activation, which downregulates the expression of pro-inflammatory genes and reduces the production of inflammatory cytokines (TNF-α, IL-1β, IL-6). In peripheral nerve tissue, this reduces neuroinflammation — a driver of neuropathic pain sensitization — and protects the axonal microenvironment from inflammatory damage. PEA also downregulates mast cell degranulation; mast cells in peripheral nerve tissue release substances that sensitize nociceptors and drive pain.

PEA’s ‘entourage effect’ with the endocannabinoid system arises from its inhibition of enzymes that break down the endocannabinoid anandamide, effectively prolonging anandamide’s anti-pain effects without directly activating CB1 or CB2 receptors. This indirect endocannabinoid modulation contributes to pain relief without psychoactivity. PEA also has direct neuroprotective effects — it reduces oxidative stress in neurons and supports Schwann cell function.

Meta-Analysis Evidence

A comprehensive 2017 meta-analysis published in Pain, analyzing 12 randomized controlled trials involving 1,188 patients, found that PEA produced statistically significant reductions in pain intensity across multiple neuropathic pain conditions compared to control. The mean reduction in pain VAS score was approximately 2.5 points on a 0–10 scale — a clinically meaningful effect that is comparable in magnitude to first-line neuropathy medications in some comparisons. The analysis covered studies in diabetic neuropathy, chemotherapy-induced neuropathy, postherpetic neuralgia, sciatic pain, and low back pain with neuropathic features.

A subsequent 2019 systematic review in CNS Drugs confirmed these findings, noting that PEA’s effect size was consistently positive across trials of varying quality and that tolerability was excellent across all studies — no serious adverse events were reported. This is a notably clean safety profile compared to gabapentin and pregabalin, which carry significant side effect burdens including sedation, cognitive effects, and weight gain.

Micronized vs. Standard PEA

Standard crystalline PEA has poor solubility and variable oral bioavailability. Micronization (reduction of particle size to the micrometer range) and ultramicronization (submicron particle size) significantly improve dissolution and absorption. Most of the positive clinical trial evidence used micronized or ultramicronized PEA (Normast in European trials). When purchasing PEA supplements, specifically look for products that state ‘micronized’ or ‘ultramicronized’ — this specification appears on quality products that use the same particle size reduction technology validated in clinical research. Standard crystalline PEA products may be less effective at equivalent doses.

PEA vs. CBD for Neuropathy

PEA and CBD (cannabidiol) are both non-psychoactive compounds with anti-inflammatory and potential pain-relieving effects, and they are sometimes compared in consumer discussions. Key differences: PEA has a more robust peer-reviewed neuropathy trial evidence base — multiple RCTs with positive outcomes, including the 2017 meta-analysis. CBD’s neuropathy-specific human trial evidence is more limited despite extensive marketing. PEA operates through a well-defined PPAR-α mechanism; CBD’s mechanism is broader and less understood for chronic pain. PEA is sold as a dietary supplement with clear dosing protocols; CBD product standardization varies widely. Both can theoretically be combined — there are no known adverse interactions. For neuropathy patients choosing between them, PEA’s more established evidence base is a meaningful differentiator.

Pros

• Multiple positive RCTs and a supportive meta-analysis across neuropathic pain conditions
• Excellent tolerability — no serious adverse events in clinical trials
• Non-psychoactive and not a controlled substance — no prescribing or legal concerns
• Complementary mechanism to ALA, B vitamins, and omega-3 — fits well in multi-supplement protocols
• Micronized form has good bioavailability relative to other lipid-soluble supplements
• Available as medical food in Europe (Normast) — suggests regulatory confidence in the evidence base

Cons

• Relatively expensive compared to ALA or B vitamins
• Less physician familiarity — many US doctors are not yet aware of the evidence
• Micronized form is essential — standard crystalline PEA products may underperform
• Effect size is meaningful but not dramatic for all patients — works best as part of a comprehensive approach

Frequently Asked Questions

Is PEA the same as CBD?

No. PEA (palmitoylethanolamide) and CBD (cannabidiol) are different compounds with different mechanisms. PEA is an endogenous fatty acid amide produced by the body; CBD is a phytocannabinoid from the cannabis plant. Both are non-psychoactive and have anti-inflammatory properties, but their mechanisms differ. PEA has a stronger neuropathy-specific evidence base from controlled trials. They can be taken together safely — no known interactions.

Can I take PEA with gabapentin or pregabalin?

Yes. PEA and gabapentin/pregabalin work through entirely different mechanisms and have no known pharmacological interactions. Several clinicians use PEA as an add-on supplement alongside first-line neuropathy medications with the goal of reducing medication doses over time as PEA’s effects accumulate. Discuss any supplement additions to your medication regimen with your prescribing physician.

How do I know if a PEA product is good quality?

Look for: (1) ‘micronized’ or ‘ultramicronized’ specified on the label, (2) PEA as the primary active ingredient (not diluted in a proprietary blend), (3) third-party testing certification (NSF, USP, or lab certificate of analysis on request), (4) a company that can document the source and purity of their PEA. Reputable brands include Nutricost, Nootropics Depot, Life Extension, and others that specify micronized form. A clean ingredient list (PEA and minimal excipients) is also a good sign.

Buy on Amazon — $40–$80 for a 60-day supply